The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results
Among cwCF aged 6-11 years, AS captured with the novel CFAbd-Score.kid<sup>Ⓒ</sup> significantly decreased during ETI treatment. Simultaneously, this proves that the recently validated CFAbd-Score.kid<sup>Ⓒ</sup> is sensitive to ETI induced changes in AS. The new questionnaire is being now implemented in clinical routine and international studies.
Authors
- Franziska Duckstein (ORCID: https://orcid.org/0000-0002-0938-8502)
- Ute Graepler-Mainka
- Carlos Zagoya (ORCID: https://orcid.org/0000-0002-1822-3750)
- Jochen G. Mainz (ORCID: https://orcid.org/0000-0003-3780-7759)
- Olaf Eickmeier (ORCID: https://orcid.org/0000-0003-2835-9886)
- Lutz Naehrlich (ORCID: https://orcid.org/0000-0002-7146-6997)
- Anton Barucha
- Louise Polte
- Suzanne van Dullemen
- Lilith Bechinger
- Pauline Sadrieh
Institutions
- Goethe University Frankfurt (DE)
- Justus-Liebig-Universität Gießen (DE)
- University Children's Hospital Tübingen (DE)
- University Hospital Frankfurt (DE)
- Universitätsklinikum Brandenburg an der Havel (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.jcf.2025.09.003
- Citations
- 3
- Primary Topic
- Hemodynamic Monitoring and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 6.02